•
in mil. unless spec.•
in mil. unless spec.•
in mil. unless spec.•
in mil. unless spec.•
in mil. unless spec.•
in mil. unless spec.Does Immunovant (IMVT) Have the Potential to Rally 30.52% as Wall Street Analysts Expect?
Don't Fight The Momentum: Roivant Has Big Expectations, But Real Pipeline Momentum
Immunovant (IMVT) Upgraded to Buy: Here's What You Should Know
Immunovant, Inc. (IMVT) Q2 2027 Earnings Call Transcript
Immunovant Meets Primary Endpoint In Difficult-To-Treat Rheumatoid Arthritis Study
What Immunovant (IMVT) Said on Its Q2 Earnings Call
Roivant Reports Financial Results for the Second Quarter Ended September 30, 2026, and Provides Business Update
Immunovant Provides Corporate Updates and Reports Financial Results for the Quarter Ended September 30, 2026
Immunovant to Report Financial Results for the Second Fiscal Quarter Ended September 30, 2026, and Provide Business Update on Monday, November 9, 2026
Kuehn Law Encourages Investors of Immunovant, Inc. to Contact Law Firm
Kuehn Law Encourages Investors of Immunovant, Inc. to Contact Law Firm
IMVT Investors with $100,000 in Losses Have Opportunity to Join Immunovant, Inc. Fraud Investigation with SBS Law
IMVT Investors with $100,000 in Losses Have Opportunity to Join Immunovant, Inc. Fraud Investigation with SBS Law
Immunovant Investigation Notice: SueWallSt Notifies Investors of Pending Investigation Into Immunovant (IMVT)
Immunovant Investigation Notice: SueWallSt Notifies Investors of Pending Investigation Into Immunovant (IMVT)
IMVT Ends Cutaneous Lupus Erythematosus Program, Stock Down
Roivant Announces Topline Results from Proof-of-Concept Study of IMVT-1402 in Cutaneous Lupus Erythematosus
Immunovant Announces Topline Results from Proof-of-Concept Study of IMVT-1402 in Cutaneous Lupus Erythematosus
Algert Global LLC Raises Position in Immunovant, Inc. $IMVT
Kuehn Law Encourages Investors of Immunovant, Inc. to Contact Law Firm